Clinical Trial Update: Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sorafenib as first-line therapy for advanced hepatocellular carcinoma in adults was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Advanced Adult Hepatocellular Carcinoma | Phase 3 | Status: TERMINATED